Skip to main content
. 2020 Sep 18;12(9):1041. doi: 10.3390/v12091041

Figure 6.

Figure 6

Inhibition of ZIKV Paraiba/2015 with the compounds (co-treatment): ZIKV Paraiba/2015 (25 PFU/well) were pre-incubated in infection media (DMEM 2% FBS) containing the indicated concentrations of the compounds (3-folds dilutions, starting concentration 100 µM) (A) Antimycin A, (B) OSU-03012 and Obatoclax, (C) Azaribine, Azauridine, and Pyrazofurin, (D) Mycophenolate mofetil, Mycophenolic acid, and AVN-944, (E) Brequinar, and (F) Aurintricarboxylic acid (ATA) for 1 h. Vero cells (96-well plates, 5 × 104 cells/well; quadruplicates) were then infected with the virus-compound mixtures and after 2 h viral absorption, media was replaced by post-infection media. At 36 h post-infection, the cells were fixed and immunoassayed with the anti-E 4G2 mAb. Plaques were counted with an automated ELISPOT reader. Dotted line indicates 50% inhibition. Data were expressed as mean and SD from three independent experiments conducted in quadruplicates.